Werewolf Therapeutics, Inc. (HOWL)
| Market Cap | 35.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -60.82M |
| Shares Out | 48.60M |
| EPS (ttm) | -1.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 831,494 |
| Open | 0.820 |
| Previous Close | 0.830 |
| Day's Range | 0.673 - 0.870 |
| 52-Week Range | 0.530 - 2.380 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+577.78%) |
| Earnings Date | May 5, 2026 |
About HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatm... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for HOWL stock is "Strong Buy." The 12-month stock price target is $5.0, which is an increase of 577.78% from the latest price.
News
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of ther...
Werewolf Therapeutics Announces Pipeline and Business Updates
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in...
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety Firs...
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – ...
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Fast Track Designation underscores the promise of Werewolf's INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: H...
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...
Werewolf Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The platform leverages native cytokines and advanced masking to enable safe, targeted immunotherapy, with WTX-124 showing strong safety and efficacy in multiple tumor types. Key milestones ahead include FDA meetings, new data releases, and pipeline expansion.
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and...
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...
Werewolf Therapeutics to Participate in the BIO International Convention
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condi...
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening
Werewolf Therapeutics Transcript: BofA Securities 2025 Healthcare Conference
The session highlighted progress on conditionally activated biologics, with WTX-124 showing promising safety and efficacy in multiple cancer types and a pivotal year ahead for regulatory discussions. Updates on the T-cell engager platform and WTX-330 are expected later this year.
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condi...
Werewolf Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025
The company highlighted progress on its PREDATOR platform, with WTX-124 showing promising monotherapy and combination activity in multiple cancers and plans for FDA engagement this year. Pipeline advances include IL-12 and IL-10 programs, with strong cash reserves supporting operations into late 2026.
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year –
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production -
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condi...
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...
Werewolf Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference
The conference highlighted progress on two clinical-stage INDUKINE programs, WTX-124 and WTX-330, both showing promising safety and efficacy in difficult-to-treat cancers. Expansion trials are ongoing, with key data readouts and regulatory milestones expected in late 2024 and 2025.
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...
Werewolf Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025
The discussion highlighted advances in conditional cytokine therapies, with WTX-124 showing promising durable responses in difficult-to-treat cancers and ongoing expansion in key indications. Strategic focus includes leveraging INDUKINE technology for next-gen biologics and optimizing IL-12 dosing.
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...